Biologics Supplier for Medspas and Dermatology in Los Angeles, CA

Physician-supervised accounts for medspas

Precision Biologics opens medspa accounts only when a supervising physician is identified and that physician's NPI number is verified, consistent with the restriction to licensed clinics, physician-supervised medspas, and physicians.

Los Angeles aesthetic groups that combine a dermatology practice, a plastic surgery practice, and a medspa under common ownership can register each supervising physician and consolidate ordering once verification is complete.

Shipping and storage for aesthetic offices

Cryopreserved Wharton's jelly formats arrive overnight on dry ice in validated containers and require -80 degree Celsius storage on receipt, suited to practices with a dedicated treatment-room freezer.

Lyophilized exosome products such as Bio EX and Bio AER ship shelf-stable at room temperature and are reconstituted per the insert included with the lot, an option smaller medspas sometimes choose to avoid cold-chain equipment altogether.

Documentation to request during vendor review

A dermatology or plastic surgery practice evaluating a new biologics supplier should ask for the certificate of analysis and lot release record for the specific lot, the donor eligibility summary, and, for Bio EX, the full ingredient disclosure covering disclosed composition.

Each lot is held in quarantine until third-party sterility testing and internal release criteria are met, which the lot release record documents. Precision Biologics also directs buyers to FDA's public statement that no exosome product is currently FDA approved, so a practice's compliance file reflects the accurate regulatory status rather than supplier claims.

Scope-of-practice and regulatory verification

Who may supervise or administer a given product at a California medspa is governed by the Medical Board of California and applicable supervision regulations, not by Precision Biologics; we recommend confirming current scope rules directly with the board and with your own counsel.

This applies equally to Wharton's jelly and exosome products, since the regulatory posture of each differs and is ultimately the practice's determination to make with its counsel.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.